These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 39089309)

  • 21. Randomized controlled trial and economic evaluation.
    Jain S; Arora NK
    Indian J Pediatr; 2000 May; 67(5):363-8. PubMed ID: 10885210
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacoeconomics: integrating economic evaluation into clinical trials.
    Haycox A; Drummond M; Walley T
    Br J Clin Pharmacol; 1997 Jun; 43(6):559-62. PubMed ID: 9205814
    [No Abstract]   [Full Text] [Related]  

  • 23. Cost-effectiveness of different study designs: an overlooked parameter in clinical research.
    Falagas ME; Bliziotis IA
    J Clin Epidemiol; 2007 Mar; 60(3):215-6. PubMed ID: 17292014
    [No Abstract]   [Full Text] [Related]  

  • 24. Cluster randomized trials: another problem for cost-effectiveness ratios.
    Flynn TN; Peters TJ
    Int J Technol Assess Health Care; 2005; 21(3):403-9. PubMed ID: 16110722
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Conceptual issues in the analysis of cost data within cluster randomized trials.
    Flynn T; Peters T
    J Health Serv Res Policy; 2005 Apr; 10(2):97-102. PubMed ID: 15831192
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estimating Cost-effectiveness of a Multimodal Ovarian Cancer Screening Program in the United States: Secondary Analysis of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
    Moss HA; Berchuck A; Neely ML; Myers ER; Havrilesky LJ
    JAMA Oncol; 2018 Feb; 4(2):190-195. PubMed ID: 29222541
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quality of health economic evaluations for the ACC/AHA stable ischemic heart disease practice guideline: A systematic review.
    Stevens ER; Farrell D; Jumkhawala SA; Ladapo JA
    Am Heart J; 2018 Oct; 204():17-33. PubMed ID: 30077048
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A critical appraisal of the Australian comparative trial of methadone and buprenorphine maintenance.
    Caplehorn J; Deeks JJ
    Drug Alcohol Rev; 2006 Mar; 25(2):157-60. PubMed ID: 16627305
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost effectiveness of medication adherence-enhancing interventions: a systematic review of trial-based economic evaluations.
    Oberjé EJ; de Kinderen RJ; Evers SM; van Woerkum CM; de Bruin M
    Pharmacoeconomics; 2013 Dec; 31(12):1155-68. PubMed ID: 24222477
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Health-related quality of life and cost-effectiveness components of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: rationale and design.
    Sullivan MD; Anderson RT; Aron D; Atkinson HH; Bastien A; Chen GJ; Feeney P; Gafni A; Hwang W; Katz LA; Narayan KM; Nwachuku C; O'Connor PJ; Zhang P;
    Am J Cardiol; 2007 Jun; 99(12A):90i-102i. PubMed ID: 17599429
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Competing or complementary? Ethical considerations and the quality of randomized trials.
    Lumley J; Bastian H
    Int J Technol Assess Health Care; 1996; 12(2):247-63. PubMed ID: 8707498
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of the feasibility and clinical value of further research to evaluate the management options for children with Down syndrome and otitis media with effusion: a feasibility study.
    Fortnum H; Leighton P; Smith MD; Brown L; Jones M; Benton C; Marder E; Marshall A; Sutton K
    Health Technol Assess; 2014 Sep; 18(60):1-147, v-vi. PubMed ID: 25270051
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of unequal randomisation to aid the economic efficiency of clinical trials.
    Torgerson DJ; Campbell MK
    BMJ; 2000 Sep; 321(7263):759. PubMed ID: 10999916
    [No Abstract]   [Full Text] [Related]  

  • 34. Analyses of cost data in economic evaluations conducted alongside randomized controlled trials.
    Doshi JA; Glick HA; Polsky D
    Value Health; 2006; 9(5):334-40. PubMed ID: 16961551
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evidence-based medicine and health economics: a case study of end stage renal disease.
    Vale L; Donaldson C; Daly C; Campbell M; Cody J; Grant A; Khan I; Lawrence P; Wallace S; MacLeod A
    Health Econ; 2000 Jun; 9(4):337-51. PubMed ID: 10862077
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Unequal randomisation can improve the economic efficiency of clinical trials.
    Torgerson D; Campbell M
    J Health Serv Res Policy; 1997 Apr; 2(2):81-5. PubMed ID: 10180369
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Using cost-effectiveness analysis to improve the efficiency of allocating funds to clinical trials.
    Detsky AS
    Stat Med; 1990; 9(1-2):173-84. PubMed ID: 2111932
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predicting clinical trial results based on announcements of interim analyses.
    Broglio KR; Stivers DN; Berry DA
    Trials; 2014 Mar; 15():73. PubMed ID: 24607270
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Economic evaluations and randomized trials in spinal disorders: principles and methods.
    Korthals-de Bos I; van Tulder M; van Dieten H; Bouter L
    Spine (Phila Pa 1976); 2004 Feb; 29(4):442-8. PubMed ID: 15094541
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost data for individual patients included in clinical studies: no amount of statistical analysis can compensate for inadequate costing methods.
    Graves N; Walker D; Raine R; Hutchings A; Roberts JA
    Health Econ; 2002 Dec; 11(8):735-9. PubMed ID: 12457373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.